Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis?

Cardiovasc Revasc Med

Cardiology Department, Cardiovascular Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. Electronic address:

Published: December 2016

We report a case of bioresorbable vascular scaffold restenosis which could be caused by abnormal resorption 17months after implantation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carrev.2016.05.013DOI Listing

Publication Analysis

Top Keywords

bioresorbable vascular
8
vascular scaffold
8
unfavorable bioresorbable
4
scaffold resorption
4
resorption restenosis?
4
restenosis? report
4
report case
4
case bioresorbable
4
scaffold restenosis
4
restenosis caused
4

Similar Publications

Effects of structural design on the mechanical performances of poly-L-lactic acid cardiovascular scaffolds using FEA and in vitro methods.

J Mech Behav Biomed Mater

December 2024

Department of Bionanosystem Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea; Department of Bionanotechnology and Bioconvergence Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea; Department of Mechanical Design Engineering, Graduate School, Jeonbuk National University, Jeonju 54896, Republic of Korea; Advanced Mechanical Components Design & Research Center, Jeonbuk National University, Jeonju 54896, Republic of Korea; Innovative Mechanobio Active Materials Based Medical Device Demonstration Center, Jeonbuk National University, Jeonju 54896, Republic of Korea. Electronic address:

Article Synopsis
  • This study aimed to explore new scaffold geometries for improving the mechanical performance of Poly-L-lactic Acid (PLLA) bioresorbable vascular scaffolds (BVS) using finite element analysis (FEA) and lab experiments.
  • Four different scaffold designs were subjected to simulations and tests, focusing on various mechanical properties like crush resistance and radial strength.
  • The results revealed that Design B outperformed others in key performance metrics, suggesting new PLLA scaffold geometries could enhance their use in cardiovascular applications.
View Article and Find Full Text PDF

Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding Risk.

JACC Cardiovasc Interv

November 2024

Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland; Faculty of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland; University of Bern, Bern, Switzerland. Electronic address:

Background: Abbreviated antiplatelet therapy (APT) reduces bleeding without increasing ischemic events in largely unselected high bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI). Diabetes mellitus (DM) is associated with higher ischemic risk, and its impact on the safety and effectiveness of abbreviated APT in HBR PCI patients remains unknown.

Objectives: This study sought to investigate the comparative effectiveness of abbreviated (1 month) vs standard (≥3 months) APT in HBR patients with and without DM after biodegradable polymer sirolimus-eluting coronary stent implantation.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of two types of bioresorbable flow diverters made from a magnesium alloy: bare and PLLA-coated, comparing their bioresorption and biocompatibility in a rabbit vascular model.
  • Both types of MgBRFDs were mechanically tested and implanted into rabbits; results showed that while both had good biocompatibility, the PLLA-coated version exhibited better preservation of structure and lower inflammation over time.
  • The research concludes that the PLLA-coated MgBRFD is more clinically feasible for human use due to its slower bioresorption rate, allowing for improved performance during the healing process.
View Article and Find Full Text PDF

Crystal structure and morphology dictate the mechanical, thermal, and degradation properties of poly l-lactide (PLLA), the structural polymer of the first clinically approved bioresorbable vascular scaffolds (BVS). New experimental methods are developed to reveal the underlying mechanisms governing structure formation during the crimping step of the BVS manufacturing process. Our research specifically examines the "U-bends" - the region where the curvature is highest and stress is maximised during crimping, which can potentially lead to failure of the device with dramatic consequences on patient life.

View Article and Find Full Text PDF

Background: Data on Absorb bioresorbable vascular scaffold (BVS) use in patients presenting with ST-segment elevation myocardial infarction (STEMI) are limited. Furthermore, Absorb studies including STEMI patients lacked a prespecified implantation technique to optimize BVS deployment. This study examines the 5-year outcomes of BVS in STEMI patients using an optimized implantation strategy and the impact of prolonged dual antiplatelet therapy (DAPT).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!